Move brings together AstraZeneca and Alexion colleagues in a purpose-built facility in Kendall Square, Cambridge, MA, a world-leading life sciences hub
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population
Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
New research labs and process development services to enable next generation therapeutics
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
Lunaphore's flagship COMET technology is the only fully-automated, high-throughput, hyperplex platform with superior tissue profiling capabilities
Subscribe To Our Newsletter & Stay Updated
